Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers

Shares of Dyne Therapeutics and Sarepta declined after Novartis' treatment for a muscle-wasting rare disease failed a clinical trial. The setback raised investor concerns that similar therapies targeting the difficult-to-treat condition could face increased development and approval risk.